Abzena Capacity Update October 2024: ADC

Abzena is a leading CRO and CDMO specializing in the development and manufacture of complex biologics, bioconjugates, and antibody-drug conjugates (ADCs). By seamlessly integrating early R&D with comprehensive cGMP manufacturing capabilities in biologics, chemistry, and conjugation, Abzena consistently delivers high-quality products and data packages that support our partners' regulatory submissions and product requirements.

Our proprietary technologies, including EpiScreen™ 2.0 for developability assessments, Composite Human Antibody™ and Composite Proteins™ for protein engineering, and the AbZelectPRo™ proven high-titer cell line, enhance our ADC offerings with homogeneous drug-to-antibody ratios through our ThioBridge™ technology. Additionally, our IND-enabling analytical technologies, such as LabZient™, are designed to mitigate risks and streamline the development process for our customers. We are also adept at transferring our partners’ technologies and creating tailored solutions for their complex biotherapeutics, ensuring a collaborative approach to achieving success.